The J-Valve TF. [Image from Genesis MedTech/JC Medical]Genesis MedTech announced today that it sold its JC Medical subsidiary and its J-Valve system to Edwards Lifesciences

J-Valve TF。[来自Genesis MedTech/JC Medical的图片]Genesis MedTech今天宣布将其JC Medical子公司及其J-Valve系统出售给Edwards Lifesciences

(NYSE: EW)

（纽约证券交易所：EW）

The deal includes the intellectual property and commercial rights of J-Valve, a transcatheter aortic valve replacement (TAVR) system. Edwards agreed to an undisclosed upfront payment, plus potential sales-based contingent milestones.

该交易包括J-Valve的知识产权和商业权利，J-Valve是一种经导管主动脉瓣置换术（TAVR）系统。爱德华兹同意一笔未公开的预付款，以及潜在的基于销售的或有里程碑。

This marks the latest M&A play from Edwards, which has been very active on that front in recent months. In July, the company struck a deal to acquire mitral valve maker Innovalve Bio Medical. Ten days later, it announced two more acquisitions — JenaValve and Endotronix — worth a combined $1.2 billion.

这标志着爱德华兹（Edwards）的最新并购剧，该剧近几个月来在这方面非常活跃。7月，该公司达成协议，收购二尖瓣制造商Innovalve Bio Medical。十天后，它宣布了另外两项收购——JenaValve和Endotronix，总价值12亿美元。

Separately, Edwards also made a series of agreements with Affluent Medical — one of which had an option to buy a subsidiary..

另外，爱德华兹还与富足医疗签订了一系列协议，其中一项协议可以选择收购子公司。

J-Valve holds FDA breakthrough device designation. Its breakthrough designation covers the treatment of severe native aortic regurgitation (AR) and AR-dominant mixed aortic valve disease. The system’s procedure takes place through a minimally invasive, transfemoral approach. It eliminates the need for open-heart procedures or extracorporeal circulation..

J-Valve拥有FDA突破性的设备名称。它的突破性名称包括治疗严重的原发性主动脉瓣关闭不全（AR）和以AR为主的混合主动脉瓣疾病。该系统的程序通过微创经股入路进行。它不需要进行心脏直视手术或体外循环。

Genesis MedTech says J-Valve’s design can potentially help treat aortic valve regurgitation. The company believes this remains an underserved population by the treatment options in the U.S.

Genesis MedTech说J-Valve的设计可能有助于治疗主动脉瓣返流。该公司认为，根据美国的治疗方案，这仍然是一个服务不足的人群。

In addition to the acquisition, Edwards made an equity investment of $25 million in Gensis MedTech. This supports the company’s product and market development efforts. Genesis has maintained the exclusive right to develop, manufacture and commercialize J-Valve in China.

除了收购，爱德华兹还对Gensis MedTech进行了2500万美元的股权投资。这支持了公司的产品和市场开发工作。Genesis拥有在中国开发、制造和商业化J型阀的专有权。

“J-Valve has unique advantages in treating aortic valve regurgitation.” said Warren Wang, chair and CEO of Genesis MedTech Group. “We hope that J-Valve can expand its global impact, enabling more patients to benefit from this innovative product. We will continue strengthening our focus on developing innovative products and explore better medical solutions to benefit more patients worldwide.”.

。“我们希望J-Valve能够扩大其全球影响力，使更多患者受益于这种创新产品。我们将继续加强对创新产品开发的关注，并探索更好的医疗解决方案，使全球更多患者受益。”